FI-700
FI-700 is an orally active FLT3 inhibitor with an IC50 of 20 nM. FI-700 induces G1 phase cell cycle arrest by inhibiting autophosphorylation of mutant FLT3 and the downstream STAT5/MAPK pathway. FI-700 triggers the mitochondrial apoptosis pathway by downregulating anti-apoptotic proteins Mcl-1 and Bcl-XL, altering the conformation of Bax, and activating caspase-3. FI-700 can be used in research related to acute myeloid leukemia.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 866883-79-6
- Fòrmula: C21H29N9O
- Peso molecular:423.51
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
STAT5 |
Mcl-1 |
Caspase-3 |
Bcl-xL |
Bax |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MV4-11 | IC50 |
0.014 μM
|
Antiproliferative activity against human leukemia MV4;11 (FLT3/ITD) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia MV4;11 (FLT3/ITD) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| HMC1 | GI50 |
74 nM
Compound: 23f
|
Antiproliferative activity against human HMC1 cells expressing FLT3-delta599 mutant after 72 hrs by WST-1 assay
Antiproliferative activity against human HMC1 cells expressing FLT3-delta599 mutant after 72 hrs by WST-1 assay
|
[PMID: 18835166] |
| MOLM-13 | IC50 |
0.016 μM
|
Antiproliferative activity against human leukemia MOLM13 (FLT3/ITD) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia MOLM13 (FLT3/ITD) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| HMC1 | GI50 |
65 nM
Compound: 23f
|
Antiproliferative activity against human HMC1 cells expressing FLT-D835Y mutant after 72 hrs by WST-1 assay
Antiproliferative activity against human HMC1 cells expressing FLT-D835Y mutant after 72 hrs by WST-1 assay
|
[PMID: 18835166] |
| Kasumi 1 | IC50 |
0.18 μM
|
Antiproliferative activity against human leukemia Kasumi-1 (c-KIT mutation) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia Kasumi-1 (c-KIT mutation) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| MOLM-13 | GI50 |
29 nM
Compound: 23f
|
Antiproliferative activity against human MOLM13 cells after 72 hrs by WST-1 assay
Antiproliferative activity against human MOLM13 cells after 72 hrs by WST-1 assay
|
[PMID: 18835166] |
| THP-1 | IC50 |
3.1 μM
|
Antiproliferative activity against human leukemia THP1 (Wt-FLT3) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia THP1 (Wt-FLT3) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| HL-60 | IC50 |
6.8 μM
|
Antiproliferative activity against human leukemia HL60 (no FLT3) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia HL60 (no FLT3) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| K562 | IC50 |
5.2 μmol/L
|
Antiproliferative activity against human leukemia K562 (BCR/ABL) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia K562 (BCR/ABL) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
| MEG-01 | IC50 |
6.1 μM
|
Antiproliferative activity against human leukemia MegO1 (BCR/ABL) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
Antiproliferative activity against human leukemia MegO1 (BCR/ABL) cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter96 Proliferation Assay.
|
17671144 |
In Vitro
FI-700 (0.01-0.1 μM; 72 h) selectively inhibits the growth of mutant FLT3 cells in human leukemia cell lines (MV4;11, MOLM-13, THP1, Kasumi-1, K562)[1].
FI-700 (0.03-1.0 μM; 6 h) inhibits constitutive phosphorylation of FLT3, STAT5 and MAPK in MOLM-13 cells[1].
FI-700 (100 nM; 48 h) selectively reduces the growth of primary human AML cells harboring FLT3/ITD or FLT3/D835Y mutations[1].
FI-700 (0.01-0.3 μM; 24 h) induces G1-phase cell cycle arrest and increases the population of sub-G1 apoptotic cells in MOLM-13 cells[1].
FI-700 (200-800 nM; 24-72 h) induces apoptosis, reduces Mcl-1 and Bcl-XL expression, induces Bax conformational changes, and activates caspase-3 in MOLM-13 cells[2].
FI-700 potently inhibits the activity of recombinant human FLT3 kinase with an IC50 of 20 nM, and exhibits relative selectivity against other tyrosine kinases as well as serine/threonine kinases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4;11, MOLM-13, THP1, Kasumi-1, HL60, K562, MegO1, and 32D transfectants
-
Concentration:0.01, 0.03, 0.05, 0.1 μM
-
Incubation Time:72 h
-
Result:Specifically inhibited the growth of leukemia cell lines carrying FLT3/ITD or FLT3/D835Y mutations, while showing lower sensitivity against cell lines expressing wild-type FLT3 or lacking FLT3.
-
Cell Line:MOLM-13 cells
-
Concentration:0.03, 0.1, 0.3, 1.0 μM
-
Incubation Time:6 h
-
Result:Dose-dependently inhibited the constitutive autophosphorylation of the target kinase, and concurrently down-regulated the phosphorylation levels of downstream STAT5 and MAPK signals.
-
Cell Line:MOLM-13 cells
-
Concentration:0.010, 0.030, 0.100, 0.300 μM
-
Incubation Time:24 h
-
Result:Led to an increase in the proportion of cells in the G1 phase and a reciprocal reduction in the S-G2 phase, significantly inducing the appearance of sub-G1 apoptotic cell populations at higher concentrations.
-
Cell Line:Primary human AML cells
-
Concentration:100 nM
-
Incubation Time:48 h
-
Result:Significantly reduced the number of primary cells carrying mutations, but did not affect the growth of wild-type cells.
-
Cell Line:MOLM-13 cells
-
Concentration:200, 400, 800 nM
-
Incubation Time:72 h
-
Result:Significantly induced apoptosis in leukemia cells, although this apoptosis-inducing effect was partially attenuated in a co-culture system with mesenchymal stromal cells (MSCs).
-
Cell Line:MOLM-13 cells
-
Concentration:800 nM
-
Incubation Time:24 h
-
Result:Led to decreased expression levels of anti-apoptotic proteins Mcl-1 and Bcl-XL, and triggered Bax conformational activation and caspase-3 cleavage activation.
In Vivo
FI-700 (200 mg/kg; p.o.; twice daily for 5 consecutive days; survival monitored up to day 60) significantly prolongs the survival of mice in the intravenous MOLM-13 xenograft mouse model[1].
FI-700 (200 mg/kg; p.o.; twice daily; for 4 consecutive days; sacrificed on day 13) exerts effects of eliminating leukemia cells in peripheral blood and bone marrow without inducing severe myelosuppression in a syngeneic transplanted C3H/Hej mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID (Fox Chase C.B-17/Icr-scidJcl, male, 5 weeks old, s.c. inoculation of MOLM-13 FLT3/ITD-positive leukemia cells, prior i.p. anti-asialo-GM1 antibody treatment)[1]
-
Dosage:100 mg/kg; 200 mg/kg
-
Administration:p.o.; b.i.d.; 5 days; for 5 days
-
Result:Significantly induced the regression of subcutaneous tumors in a dose-dependent manner.
Caused no significant body weight loss or mortality during the entire treatment course.
-
Animal Model:SCID (Fox Chase C.B-17/Icr-scidJcl, male, 5 weeks old, i.v. inoculation of MOLM-13 FLT3/ITD-positive leukemia cells, prior i.p. anti-asialo-GM1 antibody treatment)[1]
-
Dosage:200 mg/kg
-
Administration:p.o.; b.i.d.; 5 days
-
Result:Significantly prolonged the survival time of the leukemia-bearing mice compared to the conventional chemotherapeutic drug Ara-C treatment.
-
Animal Model:C3H/Hej (i.v. inoculation of FLT3/ITD-GFP-32D leukemia cells)[1]
-
Dosage:200 mg/kg
-
Administration:p.o.; b.i.d.; 4 days
-
Result:Significantly repressed the expansion of leukemia cells in the peripheral blood and bone marrow.
Resulted in significantly less bone marrow suppression (total bone marrow cell counts remained normal) and lighter spleen weight compared to standard chemotherapy (Ara-C).
Chemical Information
-
No. CAS 866883-79-6
-
Peso molecular 423.51
-
Fòrmula C21H29N9O
-
SMILES
CCCNC1=NC(NCCC2=CC=NC=C2)=NC=C1C3=NN=C(CN4CCNCC4)O3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)